Compare D Wave Quantum Inc (QBTS) vs Summit Therapeutics Inc (SMMT) Price & Performance

QBTS trades at $17.67, up 6.57% in the last session, but remains down 33% year-to-date. The stock shows a bearish technical trend with key support at $17 and resistance at $18. Fundamentally, the company reported a net loss of $355.06 million on $24.59 million in revenue for 2025, with a negative net income margin of -2,001.59% in 2026. Recent positive news includes a $100 million funding agreement with the U.S. Department of Commerce under the CHIPS Act, announced on September 8, 2026.

Despite unanimous analyst buy ratings and a $37.00 consensus price target, significant execution risks persist. High cash burn, negative profitability, and ongoing SEC investigations pose challenges. The stock's upside depends on successful commercialization of quantum technology and effective use of government funding, but near-term volatility is expected amid sector-wide pressures and macroeconomic uncertainty.

Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.

The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.